Company intelligence / Profile preview
FeRx
San Diego, California, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
FeRx developed a magnetic nanoparticle-based drug delivery system designed to deliver chemotherapy directly to tumors using an external magnet. Its lead product, MTC-doxorubicin ("MTC‑DOX"), received orphan drug designation for primary liver cancer but failed to show sufficient benefit in Phase 2 trials and was discontinued. The company ceased operations after failing to secure additional funding following disappointing clinical results[3].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeNanoparticle (specifically, magnetic targeted carrier microparticles)Biologic (potential platform use)Gene therapy vector (potential platform use)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on FeRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FeRx.